By Michael Susin

Futura Medical PLC said Monday that it will submit an application to the U.S. Food and Drug Administration for its topical gel treatment for erectile dysfunction.

The U.K. pharmaceutical developer focused on sexual health and pain relief said it remains confident of receiving U.S. marketing authorization for the treatment, or MED3000, by the end of the first quarter of 2023.

If marketing authorization is granted, MED3000 will become the first major erectile-dysfunction treatment available without a doctor's prescription in the U.S., the company said.

Shares at 0812 GMT were up 0.02 pence, or 5.3%, at 0.39 pence.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

October 03, 2022 04:43 ET (08:43 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023 Click aqui para mais gráficos Futura Medical.
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023 Click aqui para mais gráficos Futura Medical.